Arctigenin Enhances Chemosensitivity to Cisplatin in Human Nonsmall Lung Cancer H460 Cells through Downregulation of Survivin Expression

ABSTRACT Arctigenin, a dibenzylbutyrolactone lignan, enhances cisplatin‐mediated cell apoptosis in cancer cells. Here, we sought to investigate the effects of arctigenin on cisplatin‐treated non‐small‐cell lung cancer (NSCLC) H460 cells. The 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of biochemical and molecular toxicology 2014-01, Vol.28 (1), p.39-45
Main Authors: Wang, Huan-qin, Jin, Jian-jun, Wang, Jing
Format: Article
Language:English
Subjects:
Antineoplastic Agents - pharmacology
Apoptosis
Arctigenin
Base Sequence
Carcinoma, Non-Small-Cell Lung - metabolism
Carcinoma, Non-Small-Cell Lung - pathology
Cell Cycle
Cell Line, Tumor
Chemoresistance
Cisplatin
Cisplatin - pharmacology
DNA Primers
Down-Regulation - drug effects
Drug Resistance, Neoplasm
Drug Synergism
Furans - pharmacology
Humans
Inhibitor of Apoptosis Proteins - metabolism
Kinases
Lignans - pharmacology
Lung cancer
Lung Neoplasms - metabolism
Lung Neoplasms - pathology
Medical research
Non-small-cell lung cancer (NSCLC)
Polymerase Chain Reaction
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Arctigenin, a dibenzylbutyrolactone lignan, enhances cisplatin‐mediated cell apoptosis in cancer cells. Here, we sought to investigate the effects of arctigenin on cisplatin‐treated non‐small‐cell lung cancer (NSCLC) H460 cells. The 3‐(4,5‐dimethylthiazol‐2‐yl)‐2,5‐diphenyltetrazolium bromide assay and annexin‐V/propidium iodide staining were performed to analyze the proliferation and apoptosis of H460 cells. Arctigenin dose‐dependently suppressed cell proliferation and potentiated cell apoptosis, coupled with increased cleavage of caspase‐3 and poly(ADP‐ribose) polymerase. Moreover, arctigenin sensitized H460 cells to cisplatin‐induced proliferation inhibition and apoptosis. Arctigenin alone or in combination with cisplatin had a significantly lower amount of survivin. Ectopic expression of survivin decreased cell apoptosis induced by arctigenin (P < 0.05) or in combination with cisplatin (P < 0.01). Moreover, arctigenin (P < 0.05) or in combination with cisplatin (P < 0.01) induced G1/G0 cell‐cycle arrest. Our data provide evidence that arctigenin has a therapeutic potential in combina‐tion with chemotherapeutic agents for NSLC.
ISSN:1095-6670
1099-0461
DOI:10.1002/jbt.21533